Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Semaglutide is an injectable medication that treats type 2 diabetes and obesity by regulating blood sugar levels. A ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy.

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...

Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Trial confirms that oral semaglutide lowers cardiovascular risk in type 2 diabetes, regardless of SGLT2i use. Read more!

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher ...

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

This came after Sun Pharma presented the BE study report along with revised clinical trial (CT) protocol no. ICR/23/013 ver.